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ABSTRACT 
Objectives: Salivary and serum levels of interleukin-6 (IL-6) and 
interleukin-8 (IL-8) have previously been studied in oral cancer with 
conflicting results.  
Methods: We designed a controlled study to assess the correlation 
between pre-treatment salivary and serum levels of IL-6 and IL-8, and all-
cause survival and cancer recurrence in oral cancer patients.  
Results: Fifty-two oral cancer patients and 52 healthy control cases 
were selected. In univariate analysis, salivary IL-6 and IL-8 seemed to be 
more expressed in cases (p<.001 and p=.010 respectively). Multivariate 
analysis showed that higher pre-treatment saliva IL-6 levels were 
significantly associated with better survival (HR, 8.62; 95% CI, 1.21-
62.50, p=.031). 
Conclusions: To date, this is the largest prospective controlled study 
that analyses the pre-treatment salivary and serum levels of IL-6 and IL-
8 in oral cancer patients, suggesting salivary IL-6 as possible prognostic 
biomarkers, but further validation on a larger sample is still necessary.  
 
 
 
 
 
 
Key words: Oral cancer, Prognostic markers, Interleukins, Recurrence, 
and Survival. 
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INTRODUCTION 
Oral squamous cell carcinoma (OSCC) is the most frequent oral cancer, 
accounting for more than 90% of cases worldwide. Despite substantial 
improvements in diagnosis and therapy, OSCC still has a low estimated 5-
year overall survival rate of 50% even in the United States and Western 
Europe (1, 2). Knowledge of specific prognostic and predictive factors could 
be therefore crucial in determining appropriate therapy.  
Many different biological and molecular factors have been proposed as 
prognostic factors in OSCC, but they are far removed from a real impact on 
routine clinical care (3). Cytokines play an important role in the initiation and 
maintenance of inflammatory and immune responses as well as intercellular 
cross-talking (4). Interleukin-6 (IL-6) is a multifunctional cytokine synthesized 
in response to defined stimuli by a variety of different cells (5). Interleukin-8 
(IL-8) belongs to a super family of chemokines that has chemotactic activity 
for neutrophils, eosinophils, basophils, monocytes, mast cells, dendritic cells, 
natural killer (NK) cells, and lymphocytes [6]. Salivary and serum levels of IL-6 
and IL-8 have been studied in head and neck cancer but with conflicting 
results, inadequate follow-up and on different types of tumours (7-10).  
Therefore, we designed a study to assess the correlation between pre-
treatment salivary and serum levels of IL-6 and IL-8, and all-cause survival 
and cancer recurrence in OSCC patients. 
 
METHODS 
This was a prospective cohort study: the primary explanatory variable was 
pre-treatment salivary and serum IL-6 and IL-8 levels; control variables were 
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age, sex, smoking, tumour site and stage, and different treatment modalities. 
The secondary outcome variables were tumour recurrence and all-cause 
survival. 
 
Patients’ selection and control variables 
Consecutive Caucasian patients, attending the Oral Medicine Section of the 
Department of Surgical Sciences, University of Turin, between January and 
September 2008, were enrolled. Local ethical committee approval was 
obtained before the trial started and all subjects gave written informed 
consent. 
Newly diagnosed patients with biopsy proven OSCC were approached for 
participation in this study.  
Excluded were those 1) <18 years of age, 2) pregnant or breast feeding, 3) or 
with mental health issues, 4) with diagnosis of oral lichen planus, 4) or with 
clinical diagnosis of periodontitis. A group of control subjects, unrelated to the 
cases, were recruited from the population attending the University Hospital of 
Turin. All controls presented with no oral lesions.  
Demographic information, smoking, alcohol consumption, tumour site, T 
classification and neck nodes involvement, treatment, outcome and survival 
rate (at December 31st, 2012) were recorded. Tumour grade (well, moderately 
or poorly differentiated) (11), was given by two different pathologists. C-
reactive protein was also assessed. 
 
Saliva and serum collection 
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Subjects were asked to refrain from eating, drinking, or oral hygiene for at 
least one hour prior to unstimulated whole saliva collection; they rinsed out 
their mouths with tap-water and then waited at least 5 min before 
expectorating into a 50 cc Falcon tube. The tube was centrifuged at 3500 rpm 
(2600g) for 15 min at 4 °C (Hermle bench centrifuge Z300, Labnet 
International, Woodbridge, NJ 07095); the supernatant obtained was 
immediately transferred to a new tube and frozen at -80 °C. Serum samples 
were collected at the same time, by centrifuging whole venous blood at 3000 
rpm (1000g) for 10 minutes at 15°C (Hermle bench centrifuge Z300, Labnet 
International, Woodbridge, NJ 07095). The aliquots were stored at –80°C. 
 
Interleukins 
Samples were tested using ThermoScientific/Pierce Biothecnology (Rockford, 
IL, USA) ELISA kits for recombinant human IL-6 and IL-8. Cytokine protein 
levels were determined by solid phase quantitative sandwich immunoassay 
technique. The minimum detectable doses were 1.0 pg/mL for IL-6 and 2.0 
pg/mL for IL-8. All testing was performed in duplicate per manufacturer 
instructions and means were used for data reporting.  
 
Statistical analysis 
A study with 52 case patients and 52 control subjects has been planned, in 
order to detect at least a true difference in the mean response of experimental 
and control subjects of +-0.52 standard deviation with an 80% power. The 
Type I error probability associated with this test of the null hypothesis that the 
population means of the experimental and control groups are equal is 0.05. If 
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we suppose a Bonferroni setting, the detection of true difference in the mean 
response is +-1.71 standard deviation.  
Means and frequency distributions were examined for all variables. Describing 
general information, data was reported as means and standard deviation (± 
SD). Associations between salivary and serum interleukins and control 
variables were assessed by using analysis of variance. For univariate and 
multivariate analyses, interleukins were treated as a continuous variable after 
log transformation [ln(IL + 2)]. Univariate and multivariate Cox proportional 
hazards models were used to study the relation between salivary and serum 
IL-6 and IL-8, control variables, and time to recurrence and death. Time to 
recurrence and death was measured from the pre-treatment blood draw date. 
Crude and adjusted ORs were computed by using logistic regression 
analyses to assess the independent effects of control and pre-treatment 
cases’ variables. Statistical analyses were performed using the IBM-SPSS 
statistics software version 20. 
 
RESULTS 
Cases and controls were comparable with regards to age, gender and risk 
factors. 
Fifty-two cases of OSCC were selected, of whom 32 were male and 20 
female (mean age 66.19 ± 14.97 years). The follow-up period ranged from 12 
to 60 months (median of 39.4 months). During the period considered, 10 
(19.2%) patients died because of the original OSCC. There was no 
recurrence in 29 (55.8%) patients, whilst 13 (25%) developed a recurrence. 
No second primary tumours were detected. 
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Control variables and association with pre-treatment levels of interleukins 
Table 1 shows the differences between cases and controls in interleukin 
expression. In univariate analysis, salivary IL-6 and IL-8 seemed to be more 
expressed in cases (p<.001 and p=.010 respectively) than in controls; similar 
results were also present in the multivariate analysis, also adding a statistical 
larger expression of serum IL-8 (p=.006) for pre-treatment cases.  
Older persons had higher salivary and serum IL-6 levels than did younger 
persons, the converse from salivary and serum IL-8 expression, but neither 
data had statistical significance. Smokers were more likely to have higher 
salivary IL-6 levels than non-smokers. Those with larger cancers had higher 
levels of salivary IL-6 (p=.011). There was no association between salivary 
and serum interleukins and gender, cancer site, node association, serological 
inflammation data grading or treatment type; there was only a larger 
expression of salivary IL-6 and salivary IL-8 and lymph node involvement but 
again without statistical significance. 
 
IL-6, IL-8 and control variables as independent predictors of recurrence and 
survival 
The results of the univariate and multivariate Cox proportional hazards 
regression models for recurrence and survival are detailed in Table 2. Serum 
IL-6 was not included in the final model, because the levels were too low to 
perform the analysis. 
Univariate and multivariate analyses did not show that higher pre-treatment 
salivary or serum levels of interleukins were associated with recurrence. 
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Analyses showed that patients who underwent radiotherapy remained 
significantly susceptible to recurrence, even after controlling for the other 
variables.  
Univariate analysis showed that larger cancers, nodal involvement and 
chemotherapy were significantly negatively associated with survival. Both 
analyses showed that higher pre-treatment saliva IL-6 levels were significantly 
associated with survival (p<.05). Older age, nodal involvement, cancer site 
and having chemotherapy were also independently associated with poorer 
survival in the multivariate analysis, whereas gender was not associated with 
survival.  
 
DISCUSSION 
OSCC is one of the most complex malignancies to control, and only a small 
improvement has been seen in the survival rate over the last decades; the 
problem of metastasis, recurrences and difficulties in reconstruction comprise 
the main obstacles in treatment; therefore, early detection would be a 
powerful approach in improving quality of life, and outcome and survival rate 
(12). 
The use of saliva as a diagnostic bio-fluid has long been recognised, and it 
has many advantages over other specimens like blood, exfoliated cells and 
urine (13). To date, some studies based on salivary and serum cytokine 
expression profile have endeavoured to provide information relevant to 
survival rate and recurrence of OSCC, but several critical issues still need to 
be addressed before these findings can be fully utilized in patient care. One of 
the biggest problems is that samples have included not only oral cancer but 
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also oropharyngeal carcinomas - which generally have a different 
aetiopathogenesis (human papillomavirus) and a better prognosis. 
In the present study, we set out to identify whether IL-6 and IL-8 could 
potentially be useful as biomarkers for oral cancers. Interleukin 6 was 
detected at higher concentrations in the saliva of OSCC cases compared to 
controls, and IL-8 was detected at higher concentrations both in the saliva and 
in the serum of patients with OSCC. Moreover, salivary IL-6 levels have been 
demonstrated to be useful also as independent prognostic factors for OSCC 
survival rate.  
Data confirmed the hypothesis that saliva should be preferred to blood in this 
type of research, having the potential to serve as non-invasive, widely 
accessible screening tools that do not rely on the localization of a lesion for 
diagnosis; collection is also inexpensive and can be performed in any setting. 
If becoming a routine, saliva, as a diagnostic tool for OSCC, would also 
comprise a suitable instrument for population screening, monitoring of 
patients at high risk of recurrences, and subsequently for improving survival 
rates (12).  
Serum measurements of cytokines may reflect the systemic response to 
tumour development and progression, and may not be simply indicative of 
local biochemical events at the tumour site. Moreover, several studies have 
outlined the importance of autocrine IL-6 signalling in different type of 
carcinoma - such as lung, breast, skin, and in head and neck squamous cell 
carcinoma cell lines, where findings indicate that endogenous IL-6 could play 
an important role in the growth of tumour and exert its action by an autocrine 
growth mechanism. Therefore, it seems that variation of salivary levels of IL-6 
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and IL-8 could represent disease markers that could possibly reflect 
accurately tumour status (13-15). 
Higher levels of the salivary cytokines (above all IL-6) may have significant 
usefulness as surrogate biomarkers in the efficiency of chemoprevention 
therapy (7). Although, the present data is from a relatively small sample size 
(even if the biggest in oral cancer ever reported), the results are significant 
enough to merit further investigation.  
Determination of the exact mechanisms leading to increased IL-6 and IL-8 
secretion in recurrent and advanced disease might also lead to new 
therapeutic interventions or monitoring.  
To the best of our knowledge, this is the largest prospective control study that 
analyses the pre-treatment salivary and serum levels of IL-6 and IL-8 in 
OSCC patients, confirming earlier results [16], that have suggested salivary 
IL-6 and IL-8 as diagnostic biomarkers for OSSC, but further validation on a 
larger sample is still necessary in a multicentre population study. 
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TABLE I - UNIVARIATE AND MULTIVARIATE ANALYSES OF CONTROL 
AND PRE-TREATMENT CASES’ VARIABLES 
 
 Variable β SE OR CI P 
Univariate       
 Saliva IL6 1.83 .483 6.25 2.42-16.11 <.001 
 Saliva IL8 1.17 .455 3.24 1.33-7.91 .010 
 Serum IL8 0.77 .445 2.16 0.90-5.17 .083 
 Gender .10 .452 1.11 0.45-2.68 .821 
 Smoking .71 .495 2.04 0.77-5.37 .151 
 Age .69 .450 2.00 0.83-4.83 .123 
        
Multivariate       
 Saliva IL6 1.76 .641 5.83 1.66-20.47 .006 
 Saliva IL8 1.37 .640 3.95 1.12-13.84 .032 
 Serum IL8 1.88 .681 6.56 1.73-24.93 .006 
 Gender .64 .602 1.89 0.58-6.16 .288 
 Smoking .32 .628 1.38 0.40-4.74 .604 
 Age .54 .606 1.71 0.52-5.62 .375 
Legend: 
SE: Standard Error 
OR: Odds ratio 
CI: 95% Confidence Interval 
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TABLE II - UNIVARIATE AND MULTIVARIATE RATIOS OF IL6 AND IL8 
FROM COX PROPORTIONAL HAZARD REGRESSION MODELS FOR 
RECURRENCE AND DEATH EVENTS 
 
RECURRENCE EVENTS 
  U.M.R.
§
    M.M.R.
§
  
Variable Name Hazard 
Ratio 
95% CI P  Hazard 
Ratio 
95% CI P 
        
Log IL6_saliva* 1.77 0.52-5.99 .355  3.94 0.48-32.07 .200 
Log IL8_serum* 1.66 0.49-5.55 .412  2.54 0.68-14.70 .162 
Log IL8_saliva* 1.98 0.57-6.85 .278  1.52 0.25-5.88 .648 
Age (>68 vs ≤68) 2.42 0.70-8.33 .160  3.77 0.96-14.70 .056 
Gender (female vs male) 1.10 0.33-3.66 .869  1.19 0.23-6.10 .827 
pT (pT1 vs pT2 plus pT4) 2.79 0.82-9.51 .101  1.63 0.19-13.69 .650 
N (N0 vs N1 plus N2) 1.36 0.41-4.54 .618  1.73 0.44-2.13 .434 
G (G2 plus G3 vs G1) 1.51 0.40-5.75 .541  1.60 0.25-10.28 .620 
Site (others vs tongue plus floor) 1.63 0.47-5.63 .440  1.39 0.33-5.89 .650 
Surgery (yes vs no) 1.46 0.18-11.49 .718  1.71 0.04-76.92 .783 
Chemiotherapy (yes vs no) 3.14 0.87-11.23 0.78  6.06 0.43-10.75 .349 
Radiotherapy (yes vs no) 4,83 1.21-19.23 .026  5.61 1.33-23.81 .018 
        
 
DEATH EVENTS 
 
§U.M.R.=univariate model results 
§M.M.R.=multivariate model results 
* over the mediana vs under the mediana 
 
 
 
 
 
 
  U.M.R.
§
    M.M.R.
§
  
Variable Name Hazard 
Ratio 
95% CI P  Hazard 
Ratio 
95% CI P 
        
Log IL6_saliva* 4,83 1.29-29.31 .026  8.62 1.21-62.50 .031 
Log IL8_serum* 1.03 0.26-4.12 .968  1.69 0-13-2.08 .687 
Log IL8_saliva* 1.74 0.42-7.30 .448  1.16 0.09-14.70 .909 
Age (>68 vs ≤ 68) 1.09 0.69-1.69 .130  12.34 1.23-125 .033 
Gender (male vs female) 1.86 0.37-9.24 .446  2.58 0.41-16.02 .307 
pT (pT2 plus pT4 vs pT1) 1.03 1.26-83.33 .029  1.602 0.02-90.68 .819 
N (N1 plus N2 vs N0) 5.31 1.07-26.31 .041  20.05 1.63-245.89 .019 
G (G2 plus G3 vs G1) 3.31 0.40-27.03 .263  3.14 0.17-57.17 .440 
Site (others vs tongue plus floor) 2.61 0.52-12.94 .240  6.95 1.05-45.93 .044 
Surgery (no vs yes) 1.94 0.30-9.65 0.416  1.85 0.17-20.09 .612 
Chemiotherapy (yes vs no) 5.81 1.38-24.39 .016  8.13 1.38-47.6 .020 
Radiotherapy (yes vs no) 4.83 0.97-2.38 .054  2.17 0.08-58.82 .642 
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salivary and serum levels of interleukin-6 (IL-6) and interleukin-8 (IL-8) in patients 
with “pure” oral cancer. We designed a prospective controlled study to assess 
the correlation between pre-treatment salivary and serum levels of IL-6 and IL-8, 
and all-cause survival and cancer recurrence in oral cancer patients.  
Fifty-two oral cancer patients and 52 healthy control cases were selected. In 
univariate analysis, salivary IL-6 and IL-8 seemed to be more expressed in cases 
(p<.001 and p=.010 respectively). Multivariate analysis showed that higher pre-
treatment saliva IL-6 levels were significantly associated with better survival (HR, 
8.62; 95% CI, 1.21-62.50, p=.031). To date, this is the largest prospective 
controlled study that analyses the pre-treatment salivary and serum levels of IL-6 
and IL-8 in oral cancer patients, suggesting salivary IL-6 as possible prognostic 
biomarkers, but further validation on a larger sample is still necessary.  
To the best of our knowledge, similar findings have never been documented. 
Regards 
Dr. Paolo Giacomo Arduino and co-authors. 
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